EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily

Mohammed Abdulgayoom, Motaz Almahmood, Rasha Kaddoura, Rowan Mesilhy, Rita Ahmad, Mohammad S Afana, Ayman Abdullah Dalol, Awni Alshurafa, Abdulrahman F Al-Mashdali, Mohamed Yassin, Shehab F Mohamed

Clinical Lymphoma Myeloma and Leukemia · 2026-09 · 26 (9) · 595-608.e3

DOI: 10.1016/j.clml.2026.07.001 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-09. Verfasst von Mohammed Abdulgayoom und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar. Electronic address: mmohammed…. Hauptthemen laut MEDLINE: Dasatinib, Leukemia, Myeloid, Chronic-Phase, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dasatinib 100 mg once daily is effective for chronic-phase chronic myeloid leukemia (CP-CML), but dose-related toxicity may limit long-term tolerability. We therefore evaluated whether dasatinib 50 mg once daily as an initial dose strategy preserves efficacy while improving safety compared with 100 mg once daily. We performed a systematic review and meta-analysis of adults with CP-CML treated with initial dasatinib 50 mg once daily. MEDLINE via PubMed, Embase, Cochrane CENTRAL, and Web of Science were searched from inception to March 15, 2026. Direct comparative studies of dasatinib 50 mg versus 100 mg were included in the primary analysis; whereas single-arm 50 mg cohorts were summarized as supportive evidence. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Among 613 records identified, 10 reports met eligibility criteria and 7 nonoverlapping analytic reports were retained. Two studies directly compared frontline dasatinib 50 mg versus 100 mg. Twelve-month major molecular response was similar between doses (RR 1.07, 95% CI, 0.92-1.24), while complete cytogenetic response favored 50 mg in unadjusted analysis (RR 1.09, 95% CI, 1.02-1.16). Dasatinib 50 mg reduced pleural effusion (RR 0.20, 95% CI, 0.08-0.50) and thrombocytopenia (RR 0.71, 95% CI, 0.52-0.96). Supportive frontline single-arm data showed pooled 12-month MMR and CCyR proportions of 70.6% and 95.0%, respectively.Overall, initial dasatinib 50 mg once daily may preserve key efficacy outcomes while improving tolerability in CP-CML. Prospective controlled studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibLeukemia, Myeloid, Chronic-PhaseProtein Kinase InhibitorsAntineoplastic AgentsHumansDose-Response Relationship, Drug

Stichwörter der Autor:innen

Chronic-phase CMLLow-dose dasatinibMolecular responsePleural effusionTreatment tolerability

Substanzen

DasatinibProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar. Electronic address: mmohammed35@hamad.qa.
  • Department of Internal Medicine, Phoenixville Hospital Tower Health, Phoenixville, PA.
  • Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
  • Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Department of Internal Medicine, University of North Dakota, Fargo, ND.
  • Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.

Zitieren

APA

Abdulgayoom, M., Almahmood, M., Kaddoura, R., Mesilhy, R., Ahmad, R., Afana, M. S., Dalol, A. A., Alshurafa, A., Al-Mashdali, A. F., Yassin, M., & Mohamed, S. F. (2026). Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily. Clinical Lymphoma Myeloma and Leukemia, 26(9), 595-608.e3. https://doi.org/10.1016/j.clml.2026.07.001

Vancouver

Abdulgayoom M, Almahmood M, Kaddoura R, Mesilhy R, Ahmad R, Afana MS, et al. Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily. Clinical Lymphoma Myeloma and Leukemia. 2026;26(9):595-608.e3. doi:10.1016/j.clml.2026.07.001

BibTeX
@article{Abdulgayoom2026,
  author = {Abdulgayoom, Mohammed and Almahmood, Motaz and Kaddoura, Rasha and Mesilhy, Rowan and Ahmad, Rita and Afana, Mohammad S and Dalol, Ayman Abdullah and Alshurafa, Awni and Al-Mashdali, Abdulrahman F and Yassin, Mohamed and Mohamed, Shehab F},
  title = {Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {9},
  pages = {595--608.e3},
  doi = {10.1016/j.clml.2026.07.001}
}
Kostenlos starten →